Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-amino-1-(2-(4-fluorophenyl)-3-((4-fluorophenyl)amino)-5,6-dihydro-8,8-dimethylimidazo(1,2-a)pyrazin-7(8h)-yl)ethanone
2. Ganaplacide
3. Kaf156
1. Ganaplacide
2. 1261113-96-5
3. Kaf-156
4. Kaf156
5. Gnf 156
6. Gnf-156
7. Kaf 156
8. 85vmn9ju7a
9. Chembl2058833
10. 2-amino-1-(2-(4-fluorophenyl)-3-((4-fluorophenyl)amino)-5,6-dihydro-8,8-dimethylimidazo(1,2-a)pyrazin-7(8h)-yl)ethanone
11. 2-amino-1-(2-(4-fluorophenyl)-3-((4-fluorophenyl)amino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)ethanone
12. 2-amino-1-[3-(4-fluoroanilino)-2-(4-fluorophenyl)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7-yl]ethanone
13. Ethanone, 2-amino-1-(2-(4-fluorophenyl)-3-((4-fluorophenyl)amino)-5,6-dihydro-8,8-dimethylimidazo(1,2-a)pyrazin-7(8h)-yl)-
14. Ganaplacide [inn]
15. Unii-85vmn9ju7a
16. Ganaplacide [who-dd]
17. Gnf156
18. Gtpl9946
19. Schembl1047381
20. Tqr0232
21. Dtxsid701105307
22. Bcp21186
23. Ex-a6670
24. Bdbm50388532
25. Mfcd28502124
26. Akos030629999
27. Sb17068
28. As-49356
29. H11185
30. A856033
31. Q28209255
32. Kaf 156; Kaf156; Gnf-156; Gnf156; Gnf 156; Ganaplacide
| Molecular Weight | 411.4 g/mol |
|---|---|
| Molecular Formula | C22H23F2N5O |
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 76.2 |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 604 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
KAF156 (Ganaplacide), belongs to a novel class of antimalarial molecules (imidazolopiperazines), has an effect on parasite internal protein secretory pathway. A key strength of the drug is its potential to both treat and prevent malaria, including resistant strains.
Lead Product(s): Ganaplacide,Lumefantrine
Therapeutic Area: Infections and Infectious Diseases Brand Name: KAF156
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Medicines for Malaria Venture
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2022
Lead Product(s) : Ganaplacide,Lumefantrine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Medicines for Malaria Venture
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KAF156 (Ganaplacide), belongs to a novel class of antimalarial molecules (imidazolopiperazines), has an effect on parasite internal protein secretory pathway. A key strength of the drug is its potential to both treat and prevent malaria, including resist...
Brand Name : KAF156
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Ganaplacide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ganaplacide, including repackagers and relabelers. The FDA regulates Ganaplacide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ganaplacide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ganaplacide supplier is an individual or a company that provides Ganaplacide active pharmaceutical ingredient (API) or Ganaplacide finished formulations upon request. The Ganaplacide suppliers may include Ganaplacide API manufacturers, exporters, distributors and traders.
Ganaplacide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ganaplacide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ganaplacide GMP manufacturer or Ganaplacide GMP API supplier for your needs.
A Ganaplacide CoA (Certificate of Analysis) is a formal document that attests to Ganaplacide's compliance with Ganaplacide specifications and serves as a tool for batch-level quality control.
Ganaplacide CoA mostly includes findings from lab analyses of a specific batch. For each Ganaplacide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ganaplacide may be tested according to a variety of international standards, such as European Pharmacopoeia (Ganaplacide EP), Ganaplacide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ganaplacide USP).
LOOKING FOR A SUPPLIER?
